| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $13,398,305 | 2 | 100 |
| Versant Venture Capital VI, L.P. | 10 percent owner | 0 | $0 | 1 | $1.4M | $-1.4M |
| BIOTECH GROWTH N V | 10 percent owner | 0 | $0 | 1 | $12M | $-12M |
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Black Diamond Therapeutics, Inc. have bought $0 and sold $13.4M worth of Black Diamond Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Black Diamond Therapeutics, Inc. have bought $7.07M and sold $17.65M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 400,000 shares for transaction amount of $934,080 was made by BIOTECH GROWTH N V (10 percent owner) on 2023‑10‑17.
| 2025-03-19 | Sale | BIOTECH GROWTH N V | 10 percent owner | 5.78M 12.3106% | $2.07 | $12M | -1.16% | |
| 2024-08-28 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 221,600 0.3894% | $6.32 | $1.4M | -62.79% | |
| 2023-10-17 | BIOTECH GROWTH N V | 10 percent owner | 400,000 0.7707% | $2.34 | $934,080 | +100.85% | ||
| 2023-07-05 | Behbahani Ali | director | 1M 2.8199% | $5.00 | $5M | -25.62% | ||
| 2023-07-05 | RA CAPITAL MANAGEMENT, L.P. | director | 935,850 2.639% | $5.00 | $4.68M | -25.62% | ||
| 2023-06-30 | BIOTECH GROWTH N V | 10 percent owner | 1M 2.7138% | $5.00 | $5M | -28.71% | ||
| 2023-06-27 | Sale | Epstein David M. | SEE REMARKS | 25,000 0.0743% | $6.70 | $167,500 | -41.50% | |
| 2023-06-27 | BIOTECH GROWTH N V | 10 percent owner | 1.74M 4.2378% | $5.49 | $9.56M | -41.50% | ||
| 2022-12-22 | Ni Fang | SEE REMARKS | 36,363 0.0972% | $1.28 | $46,596 | +73.48% | ||
| 2022-12-21 | Ni Fang | SEE REMARKS | 20,000 0.0546% | $1.29 | $25,770 | +74.62% | ||
| 2022-10-31 | BIOTECH GROWTH N V | director | 99,801 0.268% | $2.25 | $224,912 | -6.06% | ||
| 2022-10-28 | BIOTECH GROWTH N V | director | 172,974 0.4696% | $2.18 | $376,962 | -1.58% | ||
| 2022-10-27 | BIOTECH GROWTH N V | director | 191,678 0.5124% | $1.87 | $359,224 | +12.95% | ||
| 2022-10-21 | BIOTECH GROWTH N V | director | 87,850 0.2313% | $1.51 | $132,750 | +37.97% | ||
| 2022-10-20 | BIOTECH GROWTH N V | director | 53,734 0.144% | $1.42 | $76,345 | +49.32% | ||
| 2022-10-19 | BIOTECH GROWTH N V | director | 77,689 0.2096% | $1.32 | $102,775 | +61.48% | ||
| 2022-06-29 | Ni Fang | SEE REMARKS | 25,000 0.0681% | $2.44 | $61,018 | -16.60% | ||
| 2022-04-27 | BB BIOTECH AG | 150,000 0.4047% | $2.66 | $399,480 | -22.79% | |||
| 2022-04-18 | BB BIOTECH AG | 150,000 0.4099% | $3.29 | $493,935 | -35.24% | |||
| 2022-04-12 | BB BIOTECH AG | 150,000 0.4078% | $3.42 | $513,600 | -37.46% |
| Versant Venture Capital VI, L.P. | 10 percent owner | 3726341 6.5532% | $8.68M | 1 | 28 | <0.0001% |
| BIOTECH GROWTH N V | 10 percent owner | 2733547 4.8073% | $6.37M | 9 | 1 | +10.21% |
| Behbahani Ali | director | 4448757 7.8237% | $10.37M | 2 | 0 | <0.0001% |
| BB BIOTECH AG | 4438402 7.8055% | $10.34M | 3 | 0 | <0.0001% | |
| RA CAPITAL MANAGEMENT, L.P. | director | 3213828 5.6519% | $7.49M | 1 | 0 | <0.0001% |
| Shah Rajeev M. | director | 1924164 3.3839% | $4.48M | 1 | 0 | <0.0001% |
| Bolzon Bradley J PhD | 874099 1.5372% | $2.04M | 1 | 27 | <0.0001% | |
| Flynn James E | 10 percent owner | 778790 1.3696% | $1.81M | 1 | 0 | <0.0001% |
| Epstein David M. | SEE REMARKS | 671423 1.1808% | $1.56M | 0 | 5 | |
| Ni Fang | SEE REMARKS | 125389 0.2205% | $292,156.37 | 3 | 0 | |
| Hatzis-Schoch Brent | See Remarks | 8400 0.0148% | $19,572.00 | 1 | 9 | <0.0001% |
| INGRAM ROBERT ALEXANDER | director | 5000 0.0088% | $11,650.00 | 1 | 0 | <0.0001% |
| Roberts Christopher D. | Chief Scientific Officer | 3200 0.0056% | $7,456.00 | 0 | 10 | |
| Leggett Thomas | Chief Financial Officer | 0 0% | $0 | 0 | 5 |
$5,558,275 | 76 | -5.88% | $119.25M | |
$11,468,215 | 44 | 17.78% | $163.81M | |
$48,218,096 | 42 | 0.89% | $120.52M | |
$16,245,616 | 40 | 123.58% | $140.18M | |
$140,938,207 | 36 | 14.75% | $122.55M | |
$63,049,419 | 31 | 2.87% | $126.16M | |
$294,424,120 | 20 | 1.33% | $138.71M | |
$1,239,833 | 16 | 53.23% | $130.91M | |
Black Diamond Therapeutics, Inc. (BDTX) | $178,593,887 | 15 | -14.86% | $132.49M |
$448,999,793 | 15 | -19.99% | $129.14M | |
$10,143,329 | 12 | 11.84% | $154.55M | |
$15,799,576 | 12 | -39.47% | $166.47M | |
$22,090,972 | 7 | -3.49% | $164.38M | |
$299,343 | 6 | -44.75% | $119.05M | |
$63,981 | 5 | -11.55% | $126.38M | |
$32,289,200 | 3 | -5.46% | $145.99M | |
$9,999,990 | 2 | 25.53% | $140.76M | |
$300,016 | 1 | -50.33% | $141.86M | |
$20,020,000 | 1 | -75.24% | $125.77M |
| Increased Positions | 36 | +31.86% | 2M | +4.78% |
| Decreased Positions | 44 | -38.94% | 9M | -19.15% |
| New Positions | 15 | New | 1M | New |
| Sold Out Positions | 16 | Sold Out | 1M | Sold Out |
| Total Postitions | 105 | -7.08% | 41M | -14.37% |
| T. Rowe Price Investment Management, Inc. | $18,631.00 | 18.36% | 10.47M | -267,668 | -2.49% | 2024-12-31 |
| Bellevue Group Ag | $15,162.00 | 14.94% | 8.52M | 0 | 0% | 2024-12-31 |
| Vestal Point Capital, Lp | $9,968.00 | 9.82% | 5.6M | +571,500 | +11.37% | 2024-12-31 |
| Nea Management Company, Llc | $7,919.00 | 7.81% | 4.45M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $6,182.00 | 6.09% | 3.47M | -46,389 | -1.32% | 2025-03-31 |
| Vanguard Group Inc | $4,297.00 | 4.24% | 2.41M | +95,930 | +4.14% | 2024-12-31 |
| Tang Capital Management Llc | $3,685.00 | 3.63% | 2.07M | +700,000 | +51.09% | 2024-12-31 |
| Siren, L.L.C. | $1,863.00 | 1.84% | 1.05M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $1,708.00 | 1.68% | 959,316 | +14,439 | +1.53% | 2024-12-31 |
| Renaissance Technologies Llc | $1,609.00 | 1.59% | 904,000 | +650,200 | +256.19% | 2024-12-31 |